$13.50
-1.85-12.05%
Pre-Market: Jun 26, 9:14 AM EDT
15 minutes delayed
Comments
Loading...
Range Cancer Therapeutics ETF
CNCRNASDAQ
Sector
Healthcare
Region
US
AUM
13.98M
Fund Score
Range Cancer Therapeutics ETF (NASDAQ:CNCR) Quotes, Forecast and News Summary
Range Cancer Therapeutics ETF (NASDAQ: CNCR) stock price, news, charts, stock research, profile.
| Open | - |
| High | - |
| 52 Wk High | 17.96 |
| AUM | 13.98M |
| Dividend | - |
| Ex-Div Date | - |
| Volume | - |
| Market Cap | $8.61B |
| Mgmt Fee | 0.79% |
| P/E Ratio | 31.16 |
| Prev. Close | $15.35 |
| Low | - |
| 52 Wk Low | 9.22 |
| Shares Out | 1.18M |
| Yield | - |
| Div. Freq | - |
| Avg. Volume Daily | 10.92K |
| Beta | 0.90 |
| Avg. Expense Ratio | 0.79% |
| P/B Ratio | 1.99 |
Recent News
FAQ
How do I buy Range Cancer Therapeutics ETF (CNCR) stock?
You can purchase shares of Range Cancer Therapeutics ETF (NASDAQ:CNCR) through any online brokerage.
Who are Range Cancer Therapeutics ETF (CNCR) competitors?
There are no as such competitors for Range Cancer Therapeutics ETF.
What is the target price for Range Cancer Therapeutics ETF (CNCR) stock?
There is no analysis for Range Cancer Therapeutics ETF.
What is the forecast for Range Cancer Therapeutics ETF (CNCR) stock?
There is no analysis for Range Cancer Therapeutics ETF to provide a consensus price target.
Current stock price for Range Cancer Therapeutics ETF (CNCR)?
The stock price for Range Cancer Therapeutics ETF (NASDAQ: CNCR) is $13.5 last updated June 26, 2024 at 9:14 AM EDT.
Does Range Cancer Therapeutics ETF (CNCR) pay a dividend?
A quarterly cash dividend of 0.35 per share of Class A Common Stock. The quarterly cash dividend was payable on January 2, 2018 to stockholders of record on December 28, 2017.
When is Range Cancer Therapeutics ETF (NASDAQ:CNCR) reporting earnings?
Range Cancer Therapeutics ETF does not have any upcoming earnings scheduled.
Is Range Cancer Therapeutics ETF (CNCR) going to split?
There is no upcoming split for Range Cancer Therapeutics ETF.
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Small Cap Blend |
| Fund Inception | Oct 13, 2015 |
| Managers | Brian Cooper Gabriel Tan Todd Alberico Andrew Serowik |
| Definition | Most of the stocks in this Equity Fund have average financial performance and average growth potential |
Investment Policy
The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The Fund attempts to invest all, or substantially all, of its assets in the component securities that make up the Index. Under normal circumstances, at least 80 percent of the Funds total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the Index. Exchange Traded Concepts, LLC (ETC or the Adviser), the Funds investment adviser, expects that, over time, the correlation between the Funds performance and that of the Index, before fees and expenses, will be 95 percent or better.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| JANX | Janux Therapeutics Inc... | 4.17% |
| MGNX | Macrogenics Inc | 3.27% |
| MRSN | Mersana Therapeutics I... | 3.26% |
| YMAB | Y-Mabs Therapeutics In... | 2.85% |
| FATE | Fate Therapeutics Inc | 2.74% |
| IOVA | Iovance Biotherapeutic... | 2.57% |
| AMAM | Ambrx Inc | 2.54% |
| IBRX | Immunitybio Inc. | 2.24% |
| SMMT | Summit Therapeutics Pl... | 2.07% |
| RVMD | Revolution Medicines I... | 2.02% |